Mandatory notification of trade
The 6,000 shares were purchased at an average price of NOK 13,27 per share. Mr. Bernt-Olav Røttingsnes has a new holding in Navamedic after the purchase of 6,000 shares.
For further information, please contact:
Jon W. Ringvold, CFO/IRO
E-mail: jon.ringvold@navamedic.com
Office: +47 67 11 25 44
Mobile: +47 99 15 85 34
About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world's population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. The company's products will be sold through a network of sales, marketing and distribution partners. Navamedic's product Glucomed has been approved as a medicine against osteoarthritis in 20 European countries. The product was launched in Sweden in December 2005, and Navamedic prepares product launches in further European countries in 2006.